Lim E - Search Results

1

Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.

Milioli HH, Alexandrou S, Lim E, Caldon CE. Milioli HH, et al. Among authors: lim e. Endocr Relat Cancer. 2020 May;27(5):R93-R112. doi: 10.1530/ERC-19-0501. Endocr Relat Cancer. 2020. PMID: 32061162 Review.

2

IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.

Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Yu Q. Wee ZN, et al. Among authors: lim e. Nat Commun. 2015 Oct 27;6:8746. doi: 10.1038/ncomms9746. Nat Commun. 2015. PMID: 26503059 Free PMC article.

3

Renewed interest in the progesterone receptor in breast cancer.

Lim E, Palmieri C, Tilley WD. Lim E, et al. Br J Cancer. 2016 Oct 11;115(8):909-911. doi: 10.1038/bjc.2016.303. Epub 2016 Sep 22. Br J Cancer. 2016. PMID: 27657336 Free PMC article. No abstract available.

4

Pushing estrogen receptor around in breast cancer.

Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, Palmieri C. Lim E, et al. Endocr Relat Cancer. 2016 Dec;23(12):T227-T241. doi: 10.1530/ERC-16-0427. Epub 2016 Oct 11. Endocr Relat Cancer. 2016. PMID: 27729416 Review.

5

The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.

Law AM, Lim E, Ormandy CJ, Gallego-Ortega D. Law AM, et al. Among authors: lim e. Endocr Relat Cancer. 2017 Apr;24(4):R123-R144. doi: 10.1530/ERC-16-0404. Epub 2017 Feb 13. Endocr Relat Cancer. 2017. PMID: 28193698 Free PMC article. Review.

6

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.

Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng N, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, Timpson P, O'Toole S, Watkins DN, Cox TR, Samuel MS, Martín M, Swarbrick A. Cazet AS, et al. Among authors: lim e. Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038/s41467-018-05220-6. Nat Commun. 2018. PMID: 30042390 Free PMC article. Clinical Trial.

7

Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.

Lim E, Beith J, Boyle F, de Boer R, Hui R, McCarthy N, Redfern A, Wade T, Woodward N. Lim E, et al. Asia Pac J Clin Oncol. 2018 Oct;14 Suppl 4:12-21. doi: 10.1111/ajco.13065. Asia Pac J Clin Oncol. 2018. PMID: 30288929

8

Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.

Boyle F, Beith J, Burslem K, de Boer R, Hui R, Lim E, McCarthy N, Redfern A, Woodward N. Boyle F, et al. Among authors: lim e. Asia Pac J Clin Oncol. 2018 Oct;14 Suppl 4:3-11. doi: 10.1111/ajco.13064. Asia Pac J Clin Oncol. 2018. PMID: 30288930

9

Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer.

Portman N, Alexandrou S, Carson E, Wang S, Lim E, Caldon CE. Portman N, et al. Among authors: lim e. Endocr Relat Cancer. 2019 Jan;26(1):R15-R30. doi: 10.1530/ERC-18-0317. Endocr Relat Cancer. 2019. PMID: 30389903 Review.

10

The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.

Lee KWC, Lord S, Finn RS, Lim E, Martin A, Loi S, Lynch J, Friedlander M, Lee CK. Lee KWC, et al. Among authors: lim e. Breast Cancer Res Treat. 2019 Feb;174(1):271-278. doi: 10.1007/s10549-018-5054-x. Epub 2018 Nov 21. Breast Cancer Res Treat. 2019. PMID: 30465154

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,740 results

Search Page